First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
German company Complement Therapeutics, which has a research laboratory at Stevenage Bioscience Catalyst, reports that the first patient has been dosed in a clinical trial of its trailblazing ...
aRheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain Antiphospholipid syndrome is a rare ...
FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results